Skip to main content

Table 3 Association between metformin plus sodium-glucose transporter 2 inhibitors and metformin plus insulin and study outcomes after propensity score matching

From: Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Outcomes Treatment groups McNemar test
  Metformin + SGLT-2i (n = 34) Other GLD (n = 34) p value  
In-hospital deaths 6 (17.6%) 10 (29.4%) 0.391 1.000
ICU admission, mechanical ventilation, or in-hospital death 10 (29.4%) 11 (32.4%) 0.987 0.965
In-hospital complications 19 (55.9%) 22 (64.7%) 0.620 0.201
Long-time hospital stay 6 (17.6%) 4 (11.8%) 0.732 0.838
  Metformin + insulin (n = 67) Other GLD (n = 67) p value  
In-hospital deaths 24 (35.8%) 23 (34.3%) 1.000 0.521
ICU admission, mechanical ventilation, or in-hospital death 46 (68.7%) 36 (53.7%) 0.112 0.111
In-hospital complications 44 (65.7%) 36 (53.7%) 0.218 0.480
Long-time hospital stay 15 (22.4%) 13 (19.4%) 0.832 0.870
  1. Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
  2. GLD glucose-lowering drugs, ICU intensive care unit, SGLT-2i sodium-glucose transporter 2 inhibitors